Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000012466 | SCV004042591 | uncertain significance | Creatine transporter deficiency | 2023-08-24 | reviewed by expert panel | curation | The NM_005629.4:c.259G>A variant in SLC6A8 is a missense variant predicted to cause substitution of glycine by arginine at amino acid 87 (p.Gly87Arg). This variant is absent in population databases (PM2_Supporting) and has been described in the literature in an individual for whom biochemical testing could not be performed (PMID: 15154114). The computational predictor REVEL gives a score of 0.961 which is above the thresholds predicting a damaging (>0.75) impact on SLC6A8 function (PP3). When fibroblasts deficient for this SLC6A8 variant were grown in the presence of a physiological Cr concentration (25uM), the average creatine uptake was just above the detection limit, whereas in the control fibroblasts it was significantly higher (PMID: 17465020) (PS3_Supporting). There is a ClinVar entry for this variant (Variation ID:11700). In summary, this variant meets the criteria to be classified as a Variant of Uncertain Significance for Creatine Transporter Deficiency. SLC6A8-specific ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PP3, PS3_Supporting, PM2_Supporting. (Classification approved by the ClinGen CCDS VCEP, July 13, 2023) |
Mayo Clinic Laboratories, |
RCV001508970 | SCV001715424 | likely pathogenic | not provided | 2020-06-24 | criteria provided, single submitter | clinical testing | PS3, PM2, PP3, PM6 |
OMIM | RCV000012466 | SCV000032700 | pathogenic | Creatine transporter deficiency | 2004-07-01 | no assertion criteria provided | literature only |